20662-53-7 | 4-(2-Keto-1-benzimidazolinyl)piperidine

Packsize	Purity	Availability	Price	Discounted Price
1g	95%	in stock	$77.00	$54.00
5g	95%	in stock	$277.00	$194.00

Description

• Catalog Number: AB49965
• Chemical Name: 4-(2-Keto-1-benzimidazolinyl)piperidine
• CAS Number: 20662-53-7
• Molecular Formula: C12H15N3O
• Molecular Weight: 217.267
• MDL Number: MFCD00005714
• SMILES: O=c1[nH]c2c(n1C1CCNCC1)cccc2

Computed Properties

• Complexity: 275
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 16
• Hydrogen Bond Acceptor Count: 2
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 1
• XLogP3: 1.5

Literature

• Discovery of a Chemical Tool Inhibitor Targeting the Bromodomains of TRIM24 and BRPF.

  Journal of medicinal chemistry 20160225

• Synthesis and antibacterial activities of 1-alkyl-3-methacryloyl (acryloyl) of benzimidazolone (thione) derivatives.

  International journal of molecular sciences 20120101

• Effect of nitro groups on the photo physical properties of benzimidazolone: a solvatochromic study.

  Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy 20111215

• Benzimidazolone as potent chymase inhibitor: modulation of reactive metabolite formation in the hydrophobic (P1) region.

  Bioorganic & medicinal chemistry letters 20110801

• N-aryl-benzimidazolones as novel small molecule HSP90 inhibitors.

  Bioorganic & medicinal chemistry letters 20101215

• Design, synthesis, and structure-activity relationships of 1,3-dihydrobenzimidazol-2-one analogues as anti-HIV agents.

  Bioorganic & medicinal chemistry 20090815

• Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part I: Impact of alternative halogenated privileged structures for PLD1 specificity.

  Bioorganic & medicinal chemistry letters 20090401

• Structures of six industrial benzimidazolone pigments from laboratory powder diffraction data.

  Acta crystallographica. Section B, Structural science 20090401

• Benzimidazolone-based serotonin 5-HT1A or 5-HT7R ligands: synthesis and biological evaluation.

  Bioorganic & medicinal chemistry letters 20090315

• Potent benzimidazolone-based CGRP receptor antagonists.

  Bioorganic & medicinal chemistry letters 20081201

• The SAR studies of novel CB2 selective agonists, benzimidazolone derivatives.

  Bioorganic & medicinal chemistry letters 20080601

• Towards the synthesis of new benzimidazolone derivatives with surfactant properties.

  Carbohydrate research 20080225

• Structural elucidation of rabeprazole sodium photodegradation products.

  Journal of pharmaceutical and biomedical analysis 20080107

• New 'chemical probes' to examine the role of the hFPRL1 (or ALXR) receptor in inflammation.

  Bioorganic & medicinal chemistry letters 20071201

• Potent benzimidazolone based human beta(3)-adrenergic receptor agonists.

  Bioorganic & medicinal chemistry letters 20061101

• The SAR of 4-substituted (6,6-bicyclic) piperidine cathepsin S inhibitors.

  Bioorganic & medicinal chemistry letters 20060415

• Recent advances in the solid-phase combinatorial synthetic strategies for the quinoxaline, quinazoline and benzimidazole based privileged structures.

  Mini reviews in medicinal chemistry 20060101

• Theoretical and experimental design of atypical kinase inhibitors: application to p38 MAP kinase.

  Journal of medicinal chemistry 20050908

• SAR studies of 6-aryl-1,3-dihydrobenzimidazol-2-ones as progesterone receptor antagonists.

  Bioorganic & medicinal chemistry letters 20050801

• Benzimidazolones and indoles as non-thiol farnesyltransferase inhibitors based on tipifarnib scaffold: synthesis and activity.

  Bioorganic & medicinal chemistry letters 20050602

• Discovery and SAR studies of a novel series of noncovalent cathepsin S inhibitors.

  Bioorganic & medicinal chemistry letters 20050315

• Multiple tandem mass spectrometry-based investigation of the behaviour of some thiazol-benzimidazolones and 2-benzimidazolylsulfanyl ethanones.

  European journal of mass spectrometry (Chichester, England) 20050101

• Natural modulators of large-conductance calcium-activated potassium channels.

  Planta medica 20031001

• CFTR activation in human bronchial epithelial cells by novel benzoflavone and benzimidazolone compounds.

  American journal of physiology. Lung cellular and molecular physiology 20030701

• In vitro inhibition of pimozide N-dealkylation by selective serotonin reuptake inhibitors and azithromycin.

  Journal of clinical psychopharmacology 20020401

• Rapid liquid-phase combinatorial synthesis of heterocyclic libraries.

  Methods in molecular biology (Clifton, N.J.) 20020101

• Synthesis and progesterone receptor antagonist activities of 6-aryl benzimidazolones and benzothiazolones.

  Bioorganic & medicinal chemistry letters 20011022

• N-acylated alpha-(3-pyridylmethyl)-beta-aminotetralin antagoinists of the human neuropeptide Y Y5 receptor.

  Bioorganic & medicinal chemistry letters 20000807